These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26273510)

  • 1. Osteoporosis Treatment: When to Discontinue and When to Re-start.
    Adami S; Idolazzi L; Fracassi E; Gatti D; Rossini M
    Bone Res; 2013 Dec; 1(4):323-35. PubMed ID: 26273510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making.
    Hayes KN; Winter EM; Cadarette SM; Burden AM
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33803095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
    Anagnostis P; Paschou SA; Mintziori G; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; Senturk LM; Simoncini T; Stevenson JC; Stute P; Trémollieres FA; Goulis DG
    Maturitas; 2017 Jul; 101():23-30. PubMed ID: 28539165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
    Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday.
    Villa JC; Gianakos A; Lane JM
    HSS J; 2016 Feb; 12(1):66-73. PubMed ID: 26855630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of osteoporosis after alendronate or risedronate.
    Eiken P; Vestergaard P
    Osteoporos Int; 2016 Jan; 27(1):1-12. PubMed ID: 26438307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
    Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
    Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.
    Hanley DA; McClung MR; Davison KS; Dian L; Harris ST; Miller PD; Lewiecki EM; Kendler DL;
    Am J Med; 2017 Jul; 130(7):862.e1-862.e7. PubMed ID: 28359721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
    Kamata Y; Minota S
    Arch Osteoporos; 2019 Jul; 14(1):84. PubMed ID: 31367957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of bisphosphonates in women: when to use and when to stop.
    Gatti D; Adami S; Viapiana O; Rossini M
    Expert Opin Pharmacother; 2015; 16(16):2409-21. PubMed ID: 26357942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.
    Wright NC; Foster PJ; Mudano AS; Melnick JA; Lewiecki EM; Shergy WJ; Curtis JR; Cutter GR; Danila MI; Kilgore ML; Lewis EC; Morgan SL; Redden DT; Warriner AH; Saag KG
    Osteoporos Int; 2017 Aug; 28(8):2495-2503. PubMed ID: 28540506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological management of osteoporosis - when to treat and when to stop.
    Vannucci L; Brandi ML
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1315-1322. PubMed ID: 27322492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
    Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.